The Court of Appeal in Paris has ruled that Sanofi must pay 150.7 million euros to CNAM as compensation for anti-competitive practices related to the drug Plavix.
Matei Gaginsky
International
Foto: Sylvain ROBIN / Alamy / Profimedia
Always see our news on Google
The court's decision is based on a ruling from 2013, when Sanofi was fined 40.6 million euros for actions against generic drug manufacturers. The court found that the impact of these practices persisted until 2021, although the anti-competitive behavior lasted only five months. CNAM will receive 126.2 million euros for reimbursements and fees, plus 24.5 million euros in damages. Sanofi is reviewing the ruling and considers the possibility of an appeal to the Supreme Court.
Sources
Latest News
09:31
Marile companii de tehnologie avertizează asupra unui val de atacuri cibernetice amplificate de AI și cer consolidarea securităţii cibernetice
09:05
Stocurile de rachete Patriot ale SUA în Europa, la un nivel „mai mult decât critic" din cauza războiului cu Iranul. Care sunt implicațiile pentru NATO
08:55
The violent storms in the south of the country caused destruction in Călărași County, where trees were uprooted, and a waterspout formed on the coast.
08:46
EXCLUSIVE | August 28, 2026. Trends in online searches / last 24 hours
08:28
When will Nicușor Dan appoint a new prime minister: The President of Romania announced new consultations with the parties starting from September 1
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
